Using immune responses to treat Leukemia


12Jan2018 10:00 - 11:00

PhD defence ceremony

Acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) are myeloid malignancies with a poor prognosis. Allogenic hematopoietic stem-cell transplantation (HSCT) is often used to treat these conditions, to induce a graft versus leukemia immune response. However, this is a high-risk therapy with many complications. Marijn Gillissen studies the role of B cells in GvL immune responses, with the aim of increasing our understanding of these immune responses and developing less harmful, more effective therapies.

M.A. Gillissen: Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy: B Lymphocytes versus Leukemia.


Prof. H. Spits


Dr M.D. Hazenberg


  • Agnietenkapel

    Oudezijds Voorburgwal 229 - 231 | 1012 EZ Amsterdam
    +31 (0)20 525 2362

    Go to detailpage


This event is open to the public.

Published by  University of Amsterdam